Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challen...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2014-08, Vol.3 (8), p.1-4
Main Authors: Stroh, M, Duda, DG, Takimoto, CH, Yamazaki, S, Vicini, P
Format: Article
Language:English
Subjects:
Biomarkers
Cancer therapies
Decision making
Drug development
Drug dosages
Extracellular matrix
FDA approval
Oncology
Regulatory approval
Stockholders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128; doi:10.1038/psp.2014.28; published online 06 August 2014
ISSN:2163-8306
2163-8306
DOI:10.1038/psp.2014.28